Kolesnik, O. P., and V. O. Kuzmenko. “ERCC1 As a Marker of Prognosis and Sensitivity to Platinum-Based Chemotherapy in Patients With Stage III–IV Non-Small Cell Lung Cancer”. Pathologia, no. 1, May 2020, doi:10.14739/2310-1237.2020.1.203639.